

Timothy P Hughes, David M Ross, Junia V Melo

Handbook of Chronic Myeloid Leukemia

 Adis

Timothy P Hughes, David M Ross, Junia V Melo

Handbook of Chronic Myeloid Leukemia

Timothy P Hughes, David M Ross, Junia V Melo

Handbook of Chronic Myeloid Leukemia

Timothy P Hughes MD, FRACP, FRCPA, MBBS
SA Pathology & SAHMRI
University of Adelaide
Department of Hematology
Adelaide
Australia

David M Ross MBBS, PhD, FRACP, FRCPA
University of Adelaide and Flinders University
SA Pathology
Department of Hematology
Adelaide
Australia

Junia V Melo MD, PhD, FRCPath
University of Adelaide
Department of Hematology
Adelaide
Australia

ISBN 978-3-319-08349-0 ISBN 978-3-319-08350-6 (eBook)
DOI 10.1007/978-3-319-08350-6
Springer Cham Heidelberg New York Dordrecht London

© Springer International Publishing Switzerland 2014

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. Exempted from this legal reservation are brief excerpts in connection with reviews or scholarly analysis or material supplied specifically for the purpose of being entered and executed on a computer system, for exclusive use by the purchaser of the work. Duplication of this publication or parts thereof is permitted only under the provisions of the Copyright Law of the Publisher's location, in its current version, and permission for use must always be obtained from Springer. Permissions for use may be obtained through RightsLink at the Copyright Clearance Center. Violations are liable to prosecution under the respective Copyright Law.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. While the advice and information in this book are believed to be true and accurate at the date of publication, neither the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.

Printed on acid-free paper

Springer is part of Springer Science+Business Media (www.springer.com)

Project editor: Laura Hajba

Contents

Author biographies	vii
Abbreviations	ix
Dedication	xiii
1 Introduction	1
Historical perspective	1
Epidemiology	3
Etiology	4
Clinical manifestations	4
Pathophysiology	5
References	7
2 Diagnosis	9
Diagnostic laboratory tests	9
Differential diagnosis	15
Clinical risk scores	16
References	17
3 Monitoring response to treatment	21
Hematological response	21
Cytogenetic response	21
Molecular monitoring methods	23
Rising <i>BCR-ABL</i> levels	26
Pharmacokinetics	28
Monitoring protocol in different clinical settings	28
References	30
4 Management of patients with chronic myeloid leukemia	35
Current approach to treatment	35
Which tyrosine kinase inhibitor to use?	36
Determining the treatment goals	42
Achieving treatment goals	45

Identifying high-risk patients based on early molecular response	46
Risk-adapted therapy	47
Other promising frontline approaches	48
References	49

5 Challenges of treatment: tyrosine kinase inhibitor-resistant chronic myeloid leukemia	53
Mechanisms of resistance	53
Therapeutic options for patients who fail frontline therapy	59
Other tyrosine kinase inhibitors after failure of frontline therapy	60
Allogeneic stem cell transplantation	61
References	62

Author biographies

Timothy P Hughes, MD, FRACP, FRCPA, MBBS, is Head of the Department of Hematology at SA Pathology (RAH site) and Head of Translational Leukemia Research at the South Australian Health and Medical Research Institute (SAHMRI). He also holds a Professorial Chair in leukemia research at the University of Adelaide and is a National Health and Medical Research Council (NHMRC) Practitioner Fellow. Professor Hughes' research is focused on studies of the dynamics of response, disease progression, and drug resistance in leukemia. He has published over 250 articles with over 15,000 citations. In 2009 he co-founded the International CML Foundation (iCMLf) with John Goldman and Jorge Cortes and was appointed Chair in 2014.

David M Ross, MBBS, PhD, FRACP, FRCPA, is a Consultant Hematologist in SA Pathology based at the Royal Adelaide Hospital and Flinders Medical Centre in Adelaide, Australia. He undertook his training in clinical and laboratory hematology in Adelaide and Cambridge, UK. He returned to Adelaide to undertake his PhD project on the subject of minimal residual disease in chronic myeloid leukemia (CML) with Tim Hughes, Sue Branford, and Junia Melo. Dr Ross is a member of the disease group for CML and myeloproliferative neoplasms (MPN) in the Australasian Leukemia and Lymphoma Group (ALLG) trials collaborative group. He coordinated the ALLG CML8 clinical trial of imatinib cessation in patients with stable molecular remission (TWISTER). He has been involved in numerous clinical trials in CML and MPN. His current research interests include treatment-free remission in CML and mutations in MPN.

Junia V Melo, MD, PhD, FRCPath, graduated from the Faculty of Medicine, Universidade Federal de Minas Gerais (UFMG), Brazil in 1974, did her internal medicine and hematology training in Rio de Janeiro, Brazil, and earned her PhD from the Royal Postgraduate Medical School (RPMS), University of London in 1986. She did her first post-doctoral

training in Adelaide, Australia, after which she was invited to re-join the RPMS as a team leader in the MRC/LRF Adult Leukemia Unit in 1990. She established her research group at Imperial College London & Hammersmith Hospital from 1990 to 2007, as Professor of Molecular Hematology. In 2008 she took up the positions of Head of Leukemia Research at the Division of Hematology, Centre for Cancer Biology, IMVS, Adelaide, and of Professor of Medicine at the University of Adelaide. Her main research is focused on the molecular biology and cell kinetics of chronic myeloid leukemia and related myeloproliferative disorders, and on identifying new molecular targets for the treatment of these diseases. Professor Melo is a member of the Editorial Boards of *Blood*, and *Genes, Chromosomes & Cancer*, of the American Society of Hematology (ASH), and a Fellow of the Royal College of Pathologists, UK (FRCPath). She has authored over 200 publications in peer-reviewed journals.